Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02104934
Other study ID # CGHLIAACB2013
Secondary ID
Status Completed
Phase N/A
First received March 18, 2014
Last updated April 24, 2017
Start date March 2014
Est. completion date March 2016

Study information

Verified date July 2015
Source Changi General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Total knee arthroplasty or replacement (TKA), a commonly performed surgery for osteoarthritis of the knee, is a painful procedure and requires a multimodal analgesic approach. A method for analgesia is local infiltration analgesia (LIA), where a mixture of drugs is injected around the knee joint.

Adductor canal block (ACB) is an alternative regional anaesthesia technique which has been shown to result in minimal thigh weakness.

The investigators aim to study if the analgesia provided by ACB is superior to LIA while preserving quadriceps strength.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date March 2016
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 45 Years to 85 Years
Eligibility Inclusion Criteria:

- Patients scheduled for primary TKA under single shot spinal anaesthesia, between ages 45-85 years old, American Society of Anesthesiologists (ASA) physical status 1 to 3 and BMI 18-35 kg/m2

Exclusion Criteria:

- Patients unable to give consent, inability to communicate/ cooperate, patients with regular consumption of strong opioids (morphine, oxycodone) or steroids, allergy to local anaesthetics or any drugs included in the study, patients with lower limb surgery in the preceding year, patients with pre-existing neurological deficits and patients who have contraindications for spinal anaesthesia.

Study Design


Related Conditions & MeSH terms

  • Analgesia in Total Knee Arthroplasty

Intervention

Procedure:
Adductor Canal Block


Locations

Country Name City State
Singapore Changi General Hospital Singapore

Sponsors (1)

Lead Sponsor Collaborator
Changi General Hospital

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Other Presence of Complications Hematoma, wound infection, neurological deficits, any incidence of fall up to 48 hours
Other Length of Hospital Stay Number of days till discharge Up to 30 days
Primary Morphine consumption in the first 24 hours morphine consumption in the first 24 hours (including morphine administered in recovery and via PCA). 24 hours
Secondary Pain Scores Pain scores are recorded at 1, 6, 12, 24 and 48 hours post-operatively, assessed using a visual analog scale (0-100mm) at rest and during 45 degree passive flexion of knee. 1, 6, 12, 24 hours; up to 48 hours postoperative
Secondary Morphine Consumption The balance usage after primary outcome At 48 hours
Secondary Postoperative Nausea and Vomiting Presence/absence of nausea and vomiting, and total number of episodes of vomiting Up to 48 hours
Secondary Sedation Scores Up to 48 hours
Secondary Quadriceps Strength at 24 and 48 hours
See also
  Status Clinical Trial Phase
Terminated NCT01680692 - Continuous Femoral and Tibial Nerve Blocks in TKA Patients Early Phase 1